Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860028 | 0.96 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2349578 | 0.86 | KCNK3 (0.66) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL14859725 | 0.86 | P2RX2 (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2344887 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL14096435 | 0.85 | KCNK9 (0.80) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL28329547 | 0.85 | NPC1 (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL15149595 | 0.85 | KCNK9 (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL3046207 | 0.84 | SMN1; SMN2 (0.84) | SMN1; SMN2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL2349003 | 0.84 | EPHX1 (0.73) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL14859813 | 0.84 | ALDH1A1 (0.67) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968571-B2 | Inhibitors and methods of inhibiting bacterial and viral pathogens | SIGA TECHNOLOGIES, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20170128393-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-11 | — | — | US | claimed |
| US-20130195796-A1 | Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens | SIGA TECHNOLOGIES INC. (US) | 2013-08-01 | — | — | US | claimed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| EP-2536286-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | Siga Technologies, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| WO-2011103375-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | claimed |
| US-9968571-B2 | Inhibitors and methods of inhibiting bacterial and viral pathogens | SIGA TECHNOLOGIES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968571-B2 | Inhibitors and methods of inhibiting bacterial and viral pathogens | SIGA TECHNOLOGIES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968571-B2 | Inhibitors and methods of inhibiting bacterial and viral pathogens | SIGA TECHNOLOGIES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170128393-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128393-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128393-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9566254-B2 | Inhibitors and methods of inhibiting bacterial and viral pathogens | SIGA TECHNOLOGIES, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20130195796-A1 | Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens | SIGA TECHNOLOGIES INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2583962-A2 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | disclosed |
| EP-2536286-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | Siga Technologies, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103375-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | SIGA TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130195796-A1 | Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens | TST, TPMT, EIF2AK2 | SMN1; SMN2 4006/4885ALDH1A1 3069/4885NPC1 707/4885 |
| US-20170128393-A1 | INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND VIRAL PATHOGENS | TST, TPMT, EIF2AK2 | SMN1; SMN2 4006/4885ALDH1A1 3069/4885NPC1 707/4885 |
| US-20130096138-A1 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT | UGP2, TPMT, UPP1 | SMN1; SMN2 4357/4885ALDH1A1 1884/4885NPC1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.